Efforts to implement the legalization of adult-use cannabis in New Mexico made new progress this month as regulators issued the first license to cultivate recreational marijuana in the state.
Articles
Industry Buzz Growing Rapidly Around MINDCURE’s iSTRYM
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
St. Louis Lawmakers Move To Decriminalize Marijuana Possession And Cultivation
St. Louis lawmakers have given preliminary approval to a local measure to broadly decriminalize marijuana in the city.
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
4 States That Could Legalize Recreational Cannabis In 2022
If these states do move forward with the legalization of adult use recreational cannabis, the fight for the end of nationwide cannabis prohibition could be reaching its finale.
Compass study result validates industry's hope to find alternative treatments for mental health
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Lawmakers File Bill to Federally Legalize Cannabis
The States Reform Act seeks to end the federal prohibition of cannabis.
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
12Media34!
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Bill aims to make Pennsylvania a national leader in psychoactive research
The bill would encourage research into psilocybin, the active ingredient in magic mushrooms.
DEA Boosts Psilocybin, MDMA And DMT Production Levels Again In Final Quotas For 2021
The Drug Enforcement Administration is again greatly increasing legal production quotas for illegal Schedule I drugs like psilocybin, MDMA and DMT.
Ohio Looking to Expand Medical Cannabis Program
A bill introduced in the Ohio Senate seeks to expand the state’s medical cannabis qualifying condition list to include arthritis, migraines, autism spectrum disorder, spasticity or chronic muscle spasms, hospice care, opioid use disorder, and any other condition for which a patient could benefit from cannabis use, Cleveland.com reports.